Psychotropic medication use among children in foster care: Relationship to severe psychiatric disorders

American Journal of Public Health

Volumn 89, Issue 11, 1999, Pages 1732-1735

  Zima, Bonnie T ^a,c   Bussing, Regina ^b   Crecelius, Gia M ^a   Kaufman, Aaron ^a   Belin, Thomas R ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF FLORIDA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; CENTRAL STIMULANT AGENT; NEUROLEPTIC AGENT; PSYCHOTROPIC AGENT;

ARTICLE; CHILD; DISEASE SEVERITY; DRUG EFFICACY; DRUG USE; FEMALE; FOSTER CARE; HEALTH STATUS; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE;

EID: 0032709234     PISSN: 00900036     EISSN: None     Source Type: Journal    
DOI: 10.2105/AJPH.89.11.1732     Document Type: Article

References (39)

1. Weber T. Caretakers routinely drug foster children. Los Angeles Times. May 17, 1998:A1, A30, A32.
2. American Academy of Child and Adolescent Psychiatry. Practice parameters for the assessment and treatment of children, adolescents, and adults with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 1997;36(suppl):85S-121S.
3. American Academy of Child and Adolescent Psychiatry. Practice parameters for the assessment and treatment of children and adolescents with bipolar disorder. J Am Acad Child Adolesc Psychiatry. 1997;36(suppl):157S-176S.
4. American Academy of Child and Adolescent Psychiatry. Practice parameters for the assessment and treatment of children and adolescents with schizophrenia. J Am Acad Child Adolesc Psychiatry. 1997;36(suppl):177S-193S.
5. American Academy of Child and Adolescent Psychiatry. Practice parameters for the assessment and treatment of children and adolescents with depressive disorders. J Am Acad Child Adolesc Psychiatry. 1998;37(suppl):63S-83S.
6. American Academy of Child and Adolescent Psychiatry. Practice parameters for the assessment and treatment of children and adolescents with anxiety disorders. J Am Acad Child Adolesc Psychiatry. 1997;36(suppl):69S-84S.
7. Goldman LS, Genel M, Bezman RJ, Slanetz PJ. Diagnosis and treatment of attention-deficit/ hyperactivity disorder in children and adolescents. JAMA. 1998;279:1100-1107.
8. Findling RL, Dogin JW. Psychopharmacology of ADHD: children and adolescents. J Clin Psychiatry. 1998;59(no. 7, suppl):42-49.
9. Emslie GJ, Rush AJ, Weinberg WA, et al. A double-blind, randomized, placebo-controlled trial of fluoxetine in children and adolescents with depression. Arch Gen Psychiatry. 1997;54: 1031-1037.
10. Kumra S, Frazier JA, Jacobsen LK, et al. Childhood-onset schizophrenia. A double-blind clozapine-haloperidol comparison. Arch Gen Psychiatry. 1996;53:1090-1097.
11. National Institutes of Health. Diagnosis and treatment of attention deficit hyperactivity disorder: NIH consensus statement. Available at: http://www.odp.od.nih.gov/consensus/cons/110/ 110-statement.htm. Accessed February 2, 1999.
12. Vitiello B, Jensen PS. Psychopharmacology in children and adolescents: current problems, future prospects: summary notes on the 1995 NIMH-FDA conference. J Child Adolesc Psychopharmacol. 1995;5:5-7.
13. Cooper CS, Peterson NL, Meier JH. Variables associated with disrupted placement in a select sample of abused and neglected children. Child Abuse Negl. 1987;11:75-86.
14. Pardeck JT. A profile of the child likely to experience unstable foster care. Adolescence. 1985;20:689-696.
15. Swire MR, Kavaler F. The health status of foster children. Child Welfare. 1977;56:635-653.
16. Institute for Research on Women and Families. Code Blue: Health Services for Children in Foster Care. Sacramento, Calif: Center for California Studies, California State University; 1998.
17. England MJ, Cole RF. Building systems of care for youth with serious mental illness. Hosp Community Psychiatry. 1992;43:630-633.
18. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Washington, DC: American Psychiatric Association; 1994.
19. Hodges K, Gust J. Measures of impairment for children and adolescents. J Ment Health Adm. 1995;22:403-413.
20. Hodges K, Wong MM. Psychometric characteristics of a multidimensional measure to assess impairment: the Child and Adolescent Functional Assessment Scale (CAFAS). J Child Fam Stud. 1996;5:445-467.
21. Hallfors D, Fallon T, Watson K. An examination of psychotropic drug treatment for children with serious emotional disturbance. J Emotional Behav Disord. 1998;6:56-64.
22. Shrout P, Fleiss J. Intraclass correlations: uses in assessing rater reliability. Psychol Bull. 1979;86:420-428.
23. Simeon JG. Challenges to pediatric psychopharmacology. J Psychiatry Neurosci. 1997;22: 15-17.
24. Kaplan SL, Simms RM, Busner J. Prescribing practices of outpatient child psychiatrists. J Am Acad Child Adolesc Psychiatry. 1994;33:35-44.
25. Hughes CW, Preskom SH. Pharmacokinetics in child/adolescent psychiatric disorders. Psychiatr Ann. 1994;24:76-82.
26. Allen AJ, Leonard H, Swedo SE. Current knowledge of medications for the treatment of childhood anxiety disorders. J Am Acad Child Adolesc Psychiatry. 1995;34:976-986.
27. Gittelman-Klein R, Klein DF. School phobia: diagnostic consideration in the light of imipramine effects. J Nerv Ment Dis. 1973;156: 199-215.
28. Regier DA, Kaelber CT, Rae DS, et al. Limitations of diagnostic criteria and assessment instruments for mental disorders. Arch Gen Psychiatry. 1998;55:109-115.
29. Zito JM, Safer DJ, dosReis S, Riddle MA. Racial disparity in psychotropic medications prescribed for youths with Medicaid insurance in Maryland. J Am Acad Child Adolesc Psychiatry. 1998;37:179-184.
30. Safer DJ, Krager JM. The increased rate of stimulant treatment for hyperactive/inattentive students in secondary schools. Pediatrics. 1994;94:462-464.
31. Wolraich ML, Lindgren S, Stromquist A, et al. Stimulant medication use by primary care physicians in the treatment of attention-deficit hyperactivity disorder. Pediatrics. 1990;86:95-101.
32. Cantwell DP. Attention deficit disorder. In: Dulcan MK, Herzog DB, eds. Reviews in Child and Adolescent Psychiatry. Washington, DC: American Academy of Child and Adolescent Psychiatry; 1998:9-17.
33. Birmaher B, Ryan ND, Williamson DE, et al. Childhood and adolescent depression: a review of the past 10 years, part I. In: Dulcan MK, Herzog DB, eds. Reviews in Child and Adolescent Psychiatry. Washington, DC: American Academy of Child and Adolescent Psychiatry; 1998: 35-46.
34. Volkmar FR. Childhood and adolescent psychosis: a review of the past 10 years. J Am Acad Child Adolesc Psychiatry. 1996;35:843-851.
35. Piacentini J, Shaffer D, Fisher P, et al. The Diagnostic Interview Schedule for Children-Revised Version (DISC-R), III: concurrent criterion validity. J Am Acad Child Adolesc Psychiatry. 1993;32: 658-665.
36. Robins LN. Reflections on testing the validity of psychiatric interview. Arch Gen Psychiatry. 1985;42:918-924.
37. Birmaher B, Ryan ND, Williamson DE, Brent DA. Childhood and adolescent depression: a review of the past 10 years, part II. In: Dulcan MK, Herzog DB, eds. Reviews in Child and Adolescent Psychiatry. Washington, DC: American Academy of Child and Adolescent Psychiatry; 1998:47-54.
38. Zito JM, Riddle MA. Psychiatric pharmacoepidemiology for children. Child Adolesc Psychiatr Clin N Am. 1995;4:77-95.
39. Jensen PS, Vitiello B, Leonard H, Laughren TP. Child and adolescent psychopharmacology: expanding the research base. Psychopharmacol Bull. 1994;30:3-8.